Sangamo Therapeutics shares lost more than half their value when Pfizer pulled out of a collaboration agreement.

Sangamo also noted it remains committed to advancing its therapy for Fabry disease, aiming to submit it for regulatory approval in the latter half of 2025. Barclays (LON:BARC) analysts said Pfizer ...

Pfizer’s research partnership with Sangamo Therapeutics produced a hemophilia A gene therapy that reached FDA discussions about a regulatory submission. That’s as far as the alliance will go.

Sangamo chief executive Sandy Macrae has said the company is "surprised and extremely disappointed" by Pfizer's decision to hand back rights to its experimental gene therapy for haemophilia A ...

Dec 30 (Reuters) - Sangamo Therapeutics (SGMO.O), opens new tab said on Monday that partner Pfizer (PFE.N), opens new tab has terminated their hemophilia A gene therapy co-development agreement ...

Pfizer has abandoned development of a hemophilia A gene therapy it licensed from Sangamo Therapeutics, a move that could imperil Sangamo’s future. It’s a sudden turnabout for Pfizer ...

Truist analyst Nicole Germino keeps a BUy rating on Sangamo (SGMO) after the company announced the hemophilia A gene therapy partnership was terminated with partner Pfizer (PFE), which is expected ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for moderately severe ...

Sangamo faces steep drop after Pfizer ends partnership, raising concerns about its hemophilia therapy's future ...

16:28 EST Sangamo (SGMO) down 31% at $1.61 after Pfizer decision to terminate collaboration Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top ...

Sangamo intends to explore all options to advance the program, including seeking a potential new collaboration partner. Pfizer has indicated to Sangamo that this termination reflects its decision ...